Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 -0.25%75 EV-to-EBIT is 12.00 as of Aug. 25, 2026, which is 30% below its 10-year median of 17.06. GuruFocus rates TPE:1795 with a GF Score™ of 75/100 and a GF Value™ of NT$460.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 54.93% on this metric.
Lotus Pharmaceutical Co (TPE:1795) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lotus Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$93,803 Mil.
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,914 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co EV-to-EBIT Related Terms
Lotus Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's EV-to-EBIT falls into.
Lotus Pharmaceutical Co's current Enterprise Value is NT$94,985 Mil.
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,914 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a EV-to-EBIT of 12.00 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lotus Pharmaceutical Co and its competitors. This is 30% below median its historical median of 17.06. Over the past decade, Lotus Pharmaceutical Co's EV-to-EBIT has ranged from 8.55 to 206.14. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #311 out of 690 companies in the Drug Manufacturers industry, placing it in the top 45.1%.
Is Lotus Pharmaceutical Co's EV-to-EBIT too high?
Lotus Pharmaceutical Co's current EV-to-EBIT of 12.00 is 30% below median its 10-year median of 17.06. Over the past 10 years, this metric has ranged from a low of 8.55 to a high of 206.14. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Lotus Pharmaceutical Co's value of 12.00 is 24.1% below this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #311 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #311 out of 690 companies for EV-to-EBIT. This puts Lotus Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.81. Lotus Pharmaceutical Co's value of 12.00 is 24.1% below this benchmark. Historically, Lotus Pharmaceutical Co's own EV-to-EBIT has ranged from 8.55 to 206.14 over the past decade. While the company's 10-year median is 17.06 vs. the industry median of 15.81, Lotus Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current EV-to-EBIT of 12.00 is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current EV-to-EBIT is 12.00, which is 30% below median its own 10-year median of 17.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$460.24, compared to a current price of NT$196.00 — trading 57.4% below its estimated fair value. The current EV-to-EBIT is 12.00, which is 30% below median its 10-year median of 17.06 and 24.1% below the Drug Manufacturers industry median of 15.81. Lotus Pharmaceutical Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current EV-to-EBIT is 12.00 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$196.00 is trading 57.4% below its estimated GF Value™ of NT$460.24.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
EV-to-EBIT: 12.00 (30% below median its 10-year median of 17.06)
GF Value™: NT$460.24 vs. price of NT$196.00 (57.4% below fair value)
Industry Position: 24.1% below the Drug Manufacturers median (#311 of 690)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
75GF Score
Get the complete analysis for TPE:1795
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
